

In the Specification:

At page 7, after line 2 insert:

B¹
-- The invention further pertains to derivatives of such peptide that are a pharmaceutically acceptable acid addition salt of such peptide, a pharmaceutically acceptable carboxylate salt of such peptide, a pharmaceutically acceptable lower alkyl ester of such peptide and a pharmaceutically acceptable amide of such peptide, especially when such peptide or its derivative is combined in admixture with a suitable pharmaceutically acceptable carrier. --

In the Claims:

Please cancel claims 13 and 14 without prejudice or disclaimer.

Please add the following new claims:

B²
15. A derivative of glucagon-like peptide-1 (7-37), (GLP-1 (7-37)), wherein the amino acid sequence of said derivative has the same number of amino acids as said GLP-1 (7-37), and at least 80% amino acid identity to said GLP-1 (7-37), and wherein said derivative has an insulintropic activity that exceeds the insulintropic activity of GLP-1 (1-37) and GLP-1 (1-36).

16. The derivative of claim 15, wherein said derivative has at least 90% amino acid identity to said GLP-1 (7-37).